RU2760266C2 - Новые производные фенилпропионовой кислоты и их применение - Google Patents
Новые производные фенилпропионовой кислоты и их применение Download PDFInfo
- Publication number
- RU2760266C2 RU2760266C2 RU2019121871A RU2019121871A RU2760266C2 RU 2760266 C2 RU2760266 C2 RU 2760266C2 RU 2019121871 A RU2019121871 A RU 2019121871A RU 2019121871 A RU2019121871 A RU 2019121871A RU 2760266 C2 RU2760266 C2 RU 2760266C2
- Authority
- RU
- Russia
- Prior art keywords
- oxy
- dihydro
- hex
- pyridin
- inden
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160171541 | 2016-12-15 | ||
| KR10-2016-0171541 | 2016-12-15 | ||
| KR1020170171228A KR102007633B1 (ko) | 2016-12-15 | 2017-12-13 | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| KR10-2017-0171228 | 2017-12-13 | ||
| PCT/KR2017/014757 WO2018111012A1 (en) | 2016-12-15 | 2017-12-14 | Novel phenyl propionic acid derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019121871A RU2019121871A (ru) | 2021-01-15 |
| RU2019121871A3 RU2019121871A3 (enExample) | 2021-01-15 |
| RU2760266C2 true RU2760266C2 (ru) | 2021-11-23 |
Family
ID=62559593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121871A RU2760266C2 (ru) | 2016-12-15 | 2017-12-14 | Новые производные фенилпропионовой кислоты и их применение |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11225472B2 (enExample) |
| EP (1) | EP3555076B1 (enExample) |
| JP (1) | JP6892922B2 (enExample) |
| KR (1) | KR102007633B1 (enExample) |
| CN (1) | CN110049984B (enExample) |
| AU (1) | AU2017374460B2 (enExample) |
| BR (1) | BR112019012433A2 (enExample) |
| CA (1) | CA3042528C (enExample) |
| DK (1) | DK3555076T3 (enExample) |
| ES (1) | ES2948485T3 (enExample) |
| FI (1) | FI3555076T3 (enExample) |
| HU (1) | HUE062468T2 (enExample) |
| IL (1) | IL267239B (enExample) |
| MX (1) | MX2019007071A (enExample) |
| MY (1) | MY198292A (enExample) |
| PH (1) | PH12019501251A1 (enExample) |
| PL (1) | PL3555076T3 (enExample) |
| PT (1) | PT3555076T (enExample) |
| RS (1) | RS64259B1 (enExample) |
| RU (1) | RU2760266C2 (enExample) |
| SI (1) | SI3555076T1 (enExample) |
| WO (1) | WO2018111012A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220112185A1 (en) * | 2016-12-15 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Novel phenyl propionic acid derivatives and uses thereof |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| JP2024515137A (ja) * | 2021-04-29 | 2024-04-04 | イルドン ファーマシューティカル カンパニー リミテッド | Ｇｐｒ４０アゴニスト及びｓｇｌｔ－２阻害剤を含む医薬組成物 |
| US20220409598A1 (en) * | 2021-06-21 | 2022-12-29 | Ildong Pharmaceutical Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| WO2023080299A1 (ko) * | 2021-11-08 | 2023-05-11 | 일동제약(주) | 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| KR20240084229A (ko) * | 2022-12-06 | 2024-06-13 | 유노비아 주식회사 | 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| EA011010B1 (ru) * | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP5253155B2 (ja) | 2005-06-02 | 2013-07-31 | ジェンリン ディスカバリー | 肥満治療に有用なｍａｏ−ｂ阻害剤 |
| JP5055852B2 (ja) | 2006-06-21 | 2012-10-24 | 住友大阪セメント株式会社 | 鉄資源の回収方法 |
| US20120302566A1 (en) * | 2010-12-01 | 2012-11-29 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| JP2013147443A (ja) * | 2012-01-18 | 2013-08-01 | Daiichi Sankyo Co Ltd | β置換カルボン酸誘導体 |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| WO2015044073A1 (en) * | 2013-09-26 | 2015-04-02 | Boehringer Ingelheim International Gmbh | Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists |
| US10195178B2 (en) | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| US20220112185A1 (en) * | 2016-12-15 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Novel phenyl propionic acid derivatives and uses thereof |
| JP2024515137A (ja) * | 2021-04-29 | 2024-04-04 | イルドン ファーマシューティカル カンパニー リミテッド | Ｇｐｒ４０アゴニスト及びｓｇｌｔ－２阻害剤を含む医薬組成物 |
| US20220409598A1 (en) * | 2021-06-21 | 2022-12-29 | Ildong Pharmaceutical Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| US20230022803A1 (en) * | 2021-06-25 | 2023-01-26 | Ildong Pharmaceutical Co., Ltd. | Novel crystalline form of gpr40 agonist |
-
2017
- 2017-12-13 KR KR1020170171228A patent/KR102007633B1/ko active Active
- 2017-12-14 HU HUE17880872A patent/HUE062468T2/hu unknown
- 2017-12-14 PT PT178808721T patent/PT3555076T/pt unknown
- 2017-12-14 IL IL267239A patent/IL267239B/en unknown
- 2017-12-14 MY MYPI2019003388A patent/MY198292A/en unknown
- 2017-12-14 BR BR112019012433A patent/BR112019012433A2/pt not_active Application Discontinuation
- 2017-12-14 DK DK17880872.1T patent/DK3555076T3/da active
- 2017-12-14 FI FIEP17880872.1T patent/FI3555076T3/fi active
- 2017-12-14 AU AU2017374460A patent/AU2017374460B2/en not_active Ceased
- 2017-12-14 SI SI201731367T patent/SI3555076T1/sl unknown
- 2017-12-14 RU RU2019121871A patent/RU2760266C2/ru active
- 2017-12-14 JP JP2019531649A patent/JP6892922B2/ja active Active
- 2017-12-14 PL PL17880872.1T patent/PL3555076T3/pl unknown
- 2017-12-14 EP EP17880872.1A patent/EP3555076B1/en active Active
- 2017-12-14 CA CA3042528A patent/CA3042528C/en active Active
- 2017-12-14 WO PCT/KR2017/014757 patent/WO2018111012A1/en not_active Ceased
- 2017-12-14 RS RS20230456A patent/RS64259B1/sr unknown
- 2017-12-14 ES ES17880872T patent/ES2948485T3/es active Active
- 2017-12-14 US US16/467,654 patent/US11225472B2/en active Active
- 2017-12-14 MX MX2019007071A patent/MX2019007071A/es unknown
- 2017-12-14 CN CN201780074801.4A patent/CN110049984B/zh not_active Expired - Fee Related
-
2019
- 2019-06-06 PH PH12019501251A patent/PH12019501251A1/en unknown
-
2021
- 2021-11-10 US US17/523,652 patent/US11731961B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA011010B1 (ru) * | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
Non-Patent Citations (3)
| Title |
|---|
| HOUZE J. B. et al.: "AMG 837: A potent, orally bioavailable GPR40 agonist", Bioorganic & Medicinal Chemistry Letters, 2012, vol. 22, p. 1267 - 1270. * |
| HOUZE J. B. et al.: "AMG 837: A potent, orally bioavailable GPR40 agonist", Bioorganic & Medicinal Chemistry Letters, 2012, vol. 22, p. 1267 - 1270. WALSH S. P. et al.: "3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists", Bioorganic & Medicinal Chemistry Letters, 2011, vol. 21, p. 3390 - 3394. * |
| WALSH S. P. et al.: "3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists", Bioorganic & Medicinal Chemistry Letters, 2011, vol. 21, p. 3390 - 3394. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2760266C2 (ru) | Новые производные фенилпропионовой кислоты и их применение | |
| JP6121339B2 (ja) | 芳香環化合物 | |
| WO2021244645A1 (zh) | 五元杂芳并咪唑类化合物及其应用 | |
| TW202136247A (zh) | ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式 | |
| TWI843243B (zh) | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 | |
| JP2021528394A (ja) | Ｇｌｐ−１受容体アゴニストおよびその使用 | |
| KR20250120376A (ko) | 축합환 화합물 및 이의 응용 | |
| CA3100795A1 (en) | Pyridinyl and pyrazinyl-(aza)indolsulfonamides | |
| EA007063B1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β; | |
| CN103145663B (zh) | (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用 | |
| KR20220140429A (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
| CN104326950A (zh) | 苯氧乙酸类衍生物、其制备方法及其作为药物的用途 | |
| US20220112185A1 (en) | Novel phenyl propionic acid derivatives and uses thereof | |
| KR102377981B1 (ko) | 폐 섬유증 치료용 조성물 | |
| NZ753053B2 (en) | Phenyl propionic acid derivatives and uses thereof | |
| WO2025087295A1 (zh) | 一种pi3k抑制剂及其制备方法和用途 | |
| WO2025209520A1 (zh) | 一种化合物、包含其的药物组合物及其用途 | |
| US20250250231A1 (en) | Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof | |
| CN121159527A (zh) | 一种glp-1r激动剂及其用途 | |
| CN121378215A (en) | Novel skeleton small molecule compound and application thereof | |
| HK40082417A (en) | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |